Malignant Melanoma Pricing and Reimbursement Report - Melanoma Therapies and Oncology Drugs Prices have Become Subject to Closer Scrutiny Due to their High Costs

Wednesday, January 20, 2016 8:56 AM UTC

Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2hqvvj/malignant) has announced the addition of the "Malignant Melanoma Pricing and Reimbursement" report to their offering.

With several new high cost melanoma drugs available, payer decisions on whether patients can access those drugs and under what conditions are becoming more important than ever. This report covers both analysis of past payer decisions and forward looking views based on payer interviews.

Key findings

- Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs
- US payers have few tools for the utilization management of melanoma medicines due to limited treatment options
- Yervoy, Zelboraf, and Tafinlar fared well in health technology assessments in France and Germany, but have had limited uptake in more cost conservative markets due to their high costs

Key Topics Covered:

1. Executive Summary

2. Market Context
- Market entry of new drugs will dramatically increase the budget impact of melanoma treatments
- Marketed malignant melanoma products in the US, Japan, and five major EU markets
- Pipeline malignant melanoma treatments in late-stage development
- Price assumptions
- Bibliography

3. US
- Pricing
- Reimbursement
- Bibliography

4. Japan
- Successful pricing outcomes hinge on receipt of a pricing premium
- Nivolumab was awarded a 60% innovation margin
- Bibliography

5. Five Major EU Markets
- Pricing
- Reimbursement and health technology assessment
- Bibliography

For more information visit http://www.researchandmarkets.com/research/2hqvvj/malignant



CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Oncology

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Malignant Melanoma Pricing and Reimbursement Report - Melanoma Therapies and Oncology Drugs Prices have Become Subject to Closer Scrutiny Due to their High Costs

Editor's Picks

Welcome to EconoTimes